Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 1-Jul 4:05 PM ET)
Autolus Therapeutics to Participate in Upcoming Investor Conference
Globe Newswire (Thu, 25-Jun 7:00 AM ET)
Autolus Therapeutics Receives Prix Galien UK Award
Globe Newswire (Fri, 12-Jun 4:00 AM ET)
Autolus Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 27-May 7:00 AM ET)
Globe Newswire (Thu, 21-May 5:10 PM ET)
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Globe Newswire (Thu, 14-May 7:00 AM ET)
Globe Newswire (Tue, 5-May 7:00 AM ET)
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
Globe Newswire (Wed, 29-Apr 4:05 PM ET)
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
Globe Newswire (Wed, 22-Apr 8:30 AM ET)
Market Chameleon (Tue, 25-Nov 5:33 AM ET)
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
Autolus Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AUTL.
As of July 8, 2026, AUTL stock price was flat at $1.61 with 38,063 million shares trading.
AUTL has a beta of 2.18, meaning it tends to be more sensitive to market movements. AUTL has a correlation of 0.15 to the broad based SPY ETF.
AUTL has a market cap of $428.14 million. This is considered a Small Cap stock.
Last quarter Autolus Therapeutics PLC - American Depositary Shares reported $26 million in Revenue and -$.27 earnings per share. This beat revenue expectation by $57,912 and met earnings estimates .
In the last 3 years, AUTL traded as high as $7.45 and as low as $1.11.
The top ETF exchange traded funds that AUTL belongs to (by Net Assets): IBB, GWX, QQQS, APIE, IBBQ.
AUTL has underperformed the market in the last year with a price return of -28.8% while the SPY ETF gained +20.9%. However, in the short term, AUTL had mixed performance relative to the market. It has outperformed in the last 3 months, returning +18.4% vs +13.0% return in SPY. But in the last 2 weeks, AUTL shares have been beat by the market, returning -3.0% compared to an SPY return of +1.3%.
AUTL support price is $1.53 and resistance is $1.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AUTL shares will trade within this expected range on the day.